Genocea Biosciences Inc (NASDAQ:GNCA) was the target of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 1,813,657 shares, a growth of 37.6% from the August 15th total of 1,318,383 shares. Based on an average daily volume of 366,123 shares, the days-to-cover ratio is currently 5.0 days. Currently, 3.7% of the shares of the stock are short sold.

Several analysts have recently commented on the stock. HC Wainwright set a $5.00 price target on shares of Genocea Biosciences and gave the company a “buy” rating in a research report on Thursday, August 2nd. Zacks Investment Research lowered shares of Genocea Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, July 11th. Finally, ValuEngine upgraded shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $4.41.

Several hedge funds have recently added to or reduced their stakes in the company. California State Teachers Retirement System grew its position in shares of Genocea Biosciences by 166.6% in the first quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 78,469 shares during the last quarter. Millennium Management LLC acquired a new stake in Genocea Biosciences during the fourth quarter worth approximately $145,000. Schwab Charles Investment Management Inc. acquired a new stake in Genocea Biosciences during the first quarter worth approximately $177,000. GSA Capital Partners LLP boosted its position in Genocea Biosciences by 266.9% during the first quarter. GSA Capital Partners LLP now owns 234,065 shares of the biotechnology company’s stock worth $246,000 after acquiring an additional 170,265 shares during the last quarter. Finally, LMR Partners LLP acquired a new stake in Genocea Biosciences during the second quarter worth approximately $175,000. Institutional investors and hedge funds own 60.23% of the company’s stock.

GNCA stock opened at $0.51 on Tuesday. The company has a market capitalization of $46.78 million, a PE ratio of -0.26 and a beta of 1.03. Genocea Biosciences has a 12 month low of $0.50 and a 12 month high of $5.46. The company has a current ratio of 6.84, a quick ratio of 6.84 and a debt-to-equity ratio of 0.95.

Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings results on Thursday, August 2nd. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. equities analysts anticipate that Genocea Biosciences will post -0.47 EPS for the current fiscal year.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Read More: Understanding Relative Strength Index

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.